Abstract
Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss. Janus kinase inhibitors have been registered for its management, it allows to personalize the therapy and increase its efficacy by relieving symptoms and positively affecting patients’ quality of life. This group of drugs is considered as the basic one for the treatment of alopecia areata severe forms. The issue of disease relapses after Janus kinase inhibitors cessation and safety of long-term therapy with such drugs are covered.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call